Protein Drugs

UB-551，An Innovative, Long-Acting IFNα8

UB-551 is developed using UBIP's unique patented fusion protein technology, significantly extending its half-life within the body. It offers several advantages, including high bioactivity, low dosage requirements, exceptional safety, and ease of integration into biopharmaceutical manufacturing. In addition to its applications in hepatitis B, hepatitis C, and other general interferon-related conditions, UB-551 demonstrates remarkable therapeutic efficacy in cancer treatment. It is effective against various cancer types, including but not limited to breast cancer, prostate cancer, ovarian cancer, malignant melanoma, colorectal cancer, among others. It can be used either alone or in combination with other anticancer drugs to enhance their effectiveness.

 

 

Market Potential

The global interferons market exhibited growth, increasing from USD 8.48 billion in 2022 to USD 8.82 billion in 2023. Projections suggest further growth, with an expected value of USD 10.54 billion by 2027, at a compound annual growth rate (CAGR) of 4.6%.

 
Product CodeIndicationMarketProject Progress
Pre-INDPhase I/IIPhase IIISubmissionCommercial
UB-551Chronic hepatitis B/Chronic hepatitis C/Behçet`s disease/Esophageal Squamous Cancer/Ovarian CancerTaiwan、Global
 
 
 
 
 

 

UB-851，Recombinant Human Erythropoietin (EPO)

Erythropoietin (EPO) is a glycoprotein cytokine produced by interstitial fibroblasts in the renal cortex. Its primary function is to regulate the production of red blood cells in the human body and promote the differentiation of erythropoietic precursor cells in the bone marrow into mature red blood cells. UB-851, developed in accordance with the European Pharmacopoeia with reference to the original drug, has been shown to have a similar protein structure and efficacy in both animal and human tests. The final product has successfully passed rigorous quality control inspections and analyses.

 

 

Market Potential

The global erythropoietin drugs market was valued at USD 6.87 billion in 2022 and is projected to exhibit a compound annual growth rate (CAGR) of 1.5% from 2023 to 2030.

 
Product CodeIndicationMarketProject Progress
Pre-INDPhase I/IIPhase IIISubmissionCommercial
UB-851Chronic Kidney Disease (CKD)Taiwan、Global
 
 
 
 
 

 

UB-852，An Innovative, Long-Acting Erythropoietin (EPO)

Patients suffering from renal anemia often require extended erythropoietin treatment. To prioritize patient compliance and enhance their quality of life, extending the drug's half-life is a key focus for improvement. UB-852 represents a groundbreaking, long-acting erythropoietin designed using UBIP's patented fusion technology of polysaccharide proteins. This unique approach involves fusing natural erythropoietin sequences with polysaccharide proteins, without the accumulation of chemical modifiers in the body, ensuring a high level of safety.

 

 

Market Potential

The global erythropoietin drugs market was valued at USD 6.87 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 1.5% from 2023 to 2030.

 
Product CodeIndicationMarketProject Progress
Pre-INDPhase I/IIPhase IIISubmissionCommercial
UB-852Chronic Kidney Disease (CKD)Taiwan、Global
 
 
 
 
 

 

UB-853，An Innovative, Long-Acting GCSF

G-CSF is known for its ability to stimulate the growth of myeloid cells, making it clinically valuable in cancer patients undergoing chemotherapy to mitigate the risk of Neutropenia-related infections. Additionally, it is used to mobilize peripheral blood stem cells for collection in stem cell donors. UB-853 is a groundbreaking, long-lasting granulocyte colony-stimulating hormone developed using UBI Pharma's unique fusion protein technology. It boasts several advantages, including an extended half-life, exceptional safety, robust bioactivity, and a streamlined manufacturing process.

 

 

Market Potential

The global G-CSF (Granulocyte Colony-Stimulating Factor) market demonstrated growth, increasing from USD 7.99 billion in 2022 to USD 8.43 billion in 2023. Projections indicate further growth to reach USD 9.94 billion by 2027, with a compound annual growth rate (CAGR) of 4.2%.

 
Product CodeIndicationMarketProject Progress
Pre-INDPhase I/IIPhase IIISubmissionCommercial
UB-853NeutropeniaTaiwan、Global
 
 
 
 
 

 

UB-854，Recombinant Human Factor IX

Hemophilia is a congenital genetic disorder characterized by insufficient coagulation factors in the blood, resulting in abnormal blood clotting. Hemophilia comes in various types, including A, B, and C. Hemophilia B specifically results from a deficiency of the ninth coagulation factor and affects approximately 20% of patients. UB-854 is developed using genetic engineering technology, high-yield mammalian cell line expression, and screening technology. It is produced using continuous perfusion culture technology, offering advantages in the manufacturing process and ensuring quality that adheres to the European Pharmacopoeia standards. UB-854 stands as one of the few successfully developed human ninth coagulation factors in the world.

 

 

Market Potential

The global sales of major recombinant coagulation factor products exhibited steady growth from 2010 to 2017, reaching USD 6 billion in 2017. Projections indicate further growth, with expectations to reach USD 10 billion by 2027.

 
Product CodeIndicationMarketProject Progress
Pre-INDPhase I/IIPhase IIISubmissionCommercial
UB-854Chronic Kidney Disease (CKD)Taiwan、Global